Matthew W. McClure

784 citations

21 papers · 561 indexed · h-index 10

Cardiology and Cardiovascular Medicine top 10%
Epidemiology
Surgery
Internal Medicine top 5%
Infectious Diseases

Co-authors: Sushmita Chanda Qingling Zhang Patrick F. Smith Julian Symons Lawrence M. Blatt Christopher Westland Leo Beigelman John P. DeVincenzo
Topics: Respiratory viral infections research (6 papers)Hepatitis C virus research (5 papers)Antiplatelet Therapy and Cardiovascular Diseases (4 papers)
Cited by: Internal Medicine Cardiology and Cardiovascular Medicine Epidemiology
Journals: New England Journal of Medicine Circulation Journal of the American College of Cardiology
Partner nations: United States Belgium France

In The Last Decade

Matthew W. McClure

17 papers receiving 534 citations

Peers

Countries citing papers authored by Matthew W. McClure

Since Specialization

Citations

This map shows the geographic impact of Matthew W. McClure's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew W. McClure with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew W. McClure more than expected).

Fields of papers citing papers by Matthew W. McClure

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew W. McClure. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew W. McClure. The network helps show where Matthew W. McClure may publish in the future.

Co-authorship network of co-authors of Matthew W. McClure

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew W. McClure. A scholar is included among the top collaborators of Matthew W. McClure based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew W. McClure. Matthew W. McClure is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results 2023 ·PLoS ONE ·(unknown),Matthew W. McClure,Julian Symons,Sushmita Chanda,John Fry,Patrick F. Smith,(unknown),Michaël Fayon,Kulkanya Chokephaibulkit,Rattapon Uppala,Jolanta Bernatoniene,Kenji Furuno,Thorsten Stanley,Dymphy Huntjens,James Witek,(unknown)	14
2	Safety, pharmacokinetics, and antiviral activity of single ascending doses of ALG-125755, a GalNAc-conjugated small interfering RNA, in subjects with chronic hepatitis B 2023 ·Journal of Hepatology ·Alina Jucov,Edward Gane,Megan Fitzgerald,Kha Le,Stanley Wang,(unknown),(unknown),(unknown),Kusum Gupta,D. E. R. Clark,(unknown),Leonid Beigelman,Lawrence M. Blatt,Tse‐I Lin,Sushmita Chanda,Matthew W. McClure,John Fry	4
3	Serial Point-of-care Echocardiography Performed by an Emergency Physician to Guide Thrombolytic Management of Massive Pulmonary Embolism 2020 ·Cureus ·(unknown),(unknown),Matthew W. McClure,(unknown),Eric J. Kalivoda	0
4	Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects 2018 ·PLoS ONE ·Matthew W. McClure,Elina Berliba,Tengiz Tsertsvadze,Adrian Streinu‐Cercel,Leen Vijgen,B Astruc,Alain Patat,Christopher Westland,Sushmita Chanda,Qingling Zhang,Thomas N. Kakuda,(unknown),(unknown),Leonid Beigelman,Lawrence M. Blatt,John Fry	8
5	Short‐Duration AL‐335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis 2018 ·Hepatology ·Edward Gane,Catherine Stedman,Christian Schwabe,Leen Vijgen,Sushmita Chanda,Thomas N. Kakuda,John Fry,Lawrence M. Blatt,Matthew W. McClure	3
6	Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir 2018 ·The AAPS Journal ·Elodie Valade,Thomas N. Kakuda,Matthew W. McClure,Christopher Westland,Belén Valenzuela,Sivi Ouwerkerk‐Mahadevan,Juan José Pérez Ruixo,(unknown)	10
7	Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans 2018 ·Journal of Antimicrobial Chemotherapy ·Kashyap Patel,Carl M. J. Kirkpatrick,Keith Nieforth,Sushmita Chanda,Qingling Zhang,Matthew W. McClure,John Fry,Julian Symons,Lawrence M. Blatt,Leo Beigelman,John P. DeVincenzo,Dymphy Huntjens,Patrick F. Smith	28
8	Pharmacokinetics, safety, and tolerability of the 2‐ and 3‐direct‐acting antiviral combination of AL‐335, odalasvir, and simeprevir in healthy subjects 2018 ·Pharmacology Research & Perspectives ·Thomas N. Kakuda,Matthew W. McClure,Christopher Westland,(unknown),(unknown),(unknown),(unknown),(unknown),Alain Patat,Qingling Zhang,James Hoi Po Hui,David Apelian,David B. Smith,Sushmita Chanda,John Fry	4
9	Short duration treatment with AL-335 and odalasvir, with or without simeprevir, in treatment naïve patients with hepatitis C infection with or without cirrhosis 2017 ·Journal of Hepatology ·Edward Gane,Catherine Stedman,Matthew W. McClure,David Apelian,C. Westland,(unknown),Meera Patel,Thomas N. Kakuda,Sushmita Chanda,(unknown),Leo Beigelman,David B. Smith,John Fry	4
10	Safety and Pharmacokinetics of the Respiratory Syncytial Virus Polymerase Inhibitor, ALS-8176, in Otherwise Healthy Infants Hospitalized with Acute RSV Infection 2016 ·Open Forum Infectious Diseases ·Adam Finn,Michaël Fayon,Jolanta Bernatoniene,(unknown),Rattapon Uppala,John Fry,Sushmita Chanda,Patrick F. Smith,Keith Nieforth,Kashyap Patel,(unknown),Julian Symons,Qingling Zhang,Lawrence M. Blatt,Leonid Beigelman,Matthew W. McClure	1
11	Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study 2015 ·New England Journal of Medicine ·John P. DeVincenzo,Matthew W. McClure,Julian Symons,Hosnieh Fathi,Christopher Westland,Sushmita Chanda,Rob Lambkin‐Williams,Patrick F. Smith,Qingling Zhang,Leo Beigelman,Lawrence M. Blatt,John Fry	164
12	The Anti-Respiratory Syncytial Virus (RSV) Nucleoside Analog, AL-8112, and Its Orally Bioavailable Prodrug, AL-8176, Exhibit a High Barrier to the Emergence of Viral Resistance 2015 ·Open Forum Infectious Diseases ·Jin Tae Hong,Hong Liu,(unknown),Matthew W. McClure,Sushmita Chanda,John Fry,Leo Beigelman,Lawrence M. Blatt,Julian Symons	1
13	LB-1Treatment with Oral ALS-008176, a Nucleoside Analog, Rapidly Reduces RSV Viral Load and Clinical Disease Severity in a Healthy Volunteer Challenge Study 2014 ·Open Forum Infectious Diseases ·John P. DeVincenzo,Hosnieh Fathi,Matthew W. McClure,Christopher Westland,Sushmita Chanda,Rob Lambkin‐Williams,Patrick F. Smith,Lisa M. Harrison,Julian Symons,(unknown),Qingling Zhang,Keith Nieforth,Leo Beigelman,Lawrence M. Blatt,John Fry	13
14	Abstract 10: Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Pharmacokinetic and Pharmacodynamic Study of PRT064445, a Universal Antidote for Factor Xa Inhibitors 2013 ·Arteriosclerosis Thrombosis and Vascular Biology ·Mark Crowther,(unknown),Matthew W. McClure,Uma Sinha,Genmin Lu,Mark J. Karbarz,Athiwat Hutchaleelaha,(unknown),Vandana Mathur,John T. Curnutte	34
15	PREVALENCE AND MECHANISM OF PULMONARY HYPERTENSION IN CHRONIC HEMODIALYSIS BY INVASIVE MEASUREMENTS 2012 ·Journal of the American College of Cardiology ·(unknown),(unknown),(unknown),Matthew W. McClure,Eric D. Schwartz,Alfred A. Bové,Michael E. Brown,(unknown),Nelson M. Wolf,(unknown),(unknown),Riyaz Bashir	0
16	A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y ₁₂ Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention 2012 ·Circulation Cardiovascular Interventions ·Robert C. Welsh,Sunil V. Rao,Uwe Zeymer,Vivian P. Thompson,Kurt Huber,Janusz Kochman,Matthew W. McClure,Daniel D. Gretler,Deepak L. Bhatt,C. Michael Gibson,Dominick J. Angiolillo,Paul A. Gurbel,Lisa G. Berdan,(unknown),Sergio Leonardi,Mina Madan,William J. French,Robert A. Harrington	62
17	Pharmacokinetic and Pharmacodynamic Effects of Elinogrel 2012 ·Circulation Cardiovascular Interventions ·Dominick J. Angiolillo,Robert C. Welsh,Dietmar Trenk,Franz‐Josef Neumann,Pamela B. Conley,Matthew W. McClure,Gill Stephens,Janusz Kochman,Lisa K. Jennings,Paul A. Gurbel,(unknown),Marek Dąbrowski,Jorge F. Saucedo,(unknown),Michael Buerke,Samuel Broderick,Robert A. Harrington,Sunil V. Rao	20
18	Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI) 2010 ·American Heart Journal ·Sergio Leonardi,Sunil V. Rao,Robert A. Harrington,Deepak L. Bhatt,C. Michael Gibson,Matthew T. Roe,Janusz Kochman,Kurt Huber,Uwe Zeymer,Mina Madan,Daniel D. Gretler,Matthew W. McClure,(unknown),Vivian P. Thompson,Robert C. Welsh	56
19	Clinical Significance of Thrombocytopenia During a Non–ST-Elevation Acute Coronary Syndrome 1999 ·Circulation ·Matthew W. McClure,Scott D. Berkowitz,Rodney Sparapani,Robert H. Tuttle,Neal S. Kleiman,Lisa G. Berdan,A. Michael Lincoff,Jaap W. Deckers,Rafael Díaz,Karl R. Karsch,Daniel D. Gretler,Michael M. Kitt,Maarten L. Simoons,Eric J. Topol,Robert M. Califf,Robert A. Harrington	129
20	Thrombocytopenia in a large, international trial of the GP IIb/IIIa inhibitor eptitibatide in patients with acute coronary syndromes 1998 ·Journal of the American College of Cardiology ·Matthew W. McClure,(unknown),Lisa G. Berdan,Rodney Sparapani,Eric J. Topol,(unknown),R.M. Califf,Daniel D. Gretler,K. R. Karsch,RA Harrington	5

About Matthew W. McClure

Matthew W. McClure is a scholar working on Hepatology, Epidemiology and Infectious Diseases, having authored 21 papers that have together received 561 indexed citations. Recurring topics across this work include Respiratory viral infections research (6 papers), Hepatitis C virus research (5 papers) and Antiplatelet Therapy and Cardiovascular Diseases (4 papers). The work is most often cited by research in Internal Medicine (125 citations), Cardiology and Cardiovascular Medicine (297 citations) and Epidemiology (235 citations). Matthew W. McClure has collaborated with scholars based in United States, Belgium and France. Frequent co-authors include Sushmita Chanda, Qingling Zhang, Patrick F. Smith, Julian Symons, Lawrence M. Blatt, Christopher Westland, Leo Beigelman, John P. DeVincenzo, Daniel D. Gretler and Robert A. Harrington. Their work appears in journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact